NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort
Calogero Vetro, Irene Azzali, Elisabetta Petracci, Cristina Papayannidis, Eleonora Eleuteri, Fanny Erika Palumbo, Vincenzo Federico, Nicola Fracchiolla, Patrizia Zappasodi, Maria Paola Martelli, Maria Benedetta Giannini, Lorenzo Brunetti, Raffaele Palmieri, Jacopo Nanni
TL;DR
In a study of relapsed/refractory AML patients treated with venetoclax and hypomethylating agents, NPM1 and IDH1/2 mutations did not affect treatment response or survival.
Contribution
The study shows that NPM1 and IDH1/2 mutations have limited prognostic value in relapsed/refractory AML under this treatment.
Findings
NPM1 and IDH1/2 mutations did not significantly affect response rates in the AVALON cohort.
Survival outcomes were not influenced by the presence of NPM1 or IDH1/2 mutations in treated patients.
Abstract
In the AVALON cohort of relapsed/refractory AML treated with venetoclax plus hypomethylating agents, NPM1 and IDH1/2 mutations showed no significant impact on response or survival. These findings indicate that prognostic models for relapsed AML should consider treatment context rather than baseline mutation status.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAcute Myeloid Leukemia Research · Acute Lymphoblastic Leukemia research · Chronic Myeloid Leukemia Treatments